Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03836261
Title Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Acerta Pharma BV

chronic lymphocytic leukemia


Bendamustine + Rituximab

Cyclophosphamide + Fludarabine + Rituximab

Acalabrutinib + Venetoclax

Acalabrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT

Additional content available in CKB BOOST